Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen

NCT04547855 is registered in ClinicalTrials.gov with Yonggao Mou as lead sponsor.

NCT NCT04547855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04547855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen
Lead sponsor
Yonggao Mou
Phase
Phase 2
Overall status
Unknown status
Start date
September 11, 2020
Completion date
March 11, 2023
Enrollment
54 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma